NCT04576494View on ClinicalTrials.gov

Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms)

NACompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

January 24, 2023

Study Completion Date

September 8, 2023

Conditions
Spinal Muscular Atrophy
Interventions
OTHER

Monthly assessments of functional motor abilities by a trained therapist

Monthly assessments of functional motor abilities in adult 5q-SMA type 2 and type 3 patients by a trained therapist

DRUG

Nusinersen

nusinersen

Trial Locations (1)

Unknown

Damien JOLLY, Reims

All Listed Sponsors
lead

CHU de Reims

OTHER